News & Press

GeNeuro publishes its 2022 Universal Registration Document

Geneva, Switzerland, May 2, 2023 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19, (PASC, post-COVID or Long-COVID), publishes its 2022 Universal Registration Document, in English, which has been filed on April 28, 2023 with the “Autorité des Marchés Financiers (AMF)”.

https://geneuro.ch/data/news/GeNeuro-PR-Filing-URD-2022-EN.pdf

GeNeuro: financial information for the first quarter 2023

Geneva, Switzerland, April 13, 2023 – 6.00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today reported on its 2023 first quarter cash position.

https://geneuro.ch/data/news/GeNeuro-PR-Q1-2023-EN-vf.pdf

GeNeuro Reports 2022 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 5, 2023 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19, (PASC, post-COVID or Long-COVID), reports today its full-year results for the year ended December 31, 2022 and provided a corporate update.

https://geneuro.ch/data/news/GeNeuro-PR-FY-2022-results-EN-VF.pdf

The EIB and GeNeuro sign a EUR 25 million credit line backed by InvestEU to support clinical developments against long-COVID

Geneva, Switzerland, March 7, 2023 – 07:30 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19, (PASC, post-COVID or Long-COVID), announced today the signature of a credit agreement for a total amount of up to EUR 25 million with the European Investment Bank (“EIB”), supported by the InvestEU programme.

https://geneuro.ch/data/news/GeNeuro-PR-BEI-070323-ENG.pdf

GeNeuro announces recruitment of first patients in all five Swiss centers in the first personalized medicine clinical trial against long-COVID assessing temelimab

Geneva, Switzerland, November 16, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the recruitment of first patients in its Phase 2 trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic (lead centre), as well as in all the other Swiss clinical centres participating to the study, i.e.,  Inselspital in Bern, REHAB Basel, Kantonsspital Graubünden in Chur and the Centre Hospitalier du Valais Romand in Sion (for more information, please refer to clinical trials.gov or to GeNeuro’s web site).

https://geneuro.ch/data/news/GeNeuro-Long-COVID-First-Patients-PR-November-16-2022.pdf

GeNeuro’s ProTEct-MS Phase 2 trial data, presented at the ECTRIMS 2022 Congress in Amsterdam, confirms synergistic neuroprotective potential of temelimab in MS

Geneva, Switzerland, October 28, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced that the primary analysis of the Phase 2 ProTEct-MS study was presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022) Congress in Amsterdam, Netherlands, by Dr. Fredrik Piehl, Professor of Neurology at the Department of Clinical Neurosciences of the Karolinska Institutet, head of research at the MS clinic of the Academic Specialist Center (ASC),  and Principal Investigator of the study.

https://geneuro.ch/data/news/GeNeuro-ECTRIMS-PR-Oct.-28-2022.pdf

The Karolinska Institutet’s Academic Specialist Center (ASC) to Present Results of GeNeuro’s ProTEct-MS Phase 2 Study of Temelimab at ECTRIMS 2022

Geneva, Switzerland, October 25, 2022, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), announced it will present Phase IIb safety and efficacy data on temelimab from its ProTEct-MS study at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Amsterdam, Netherlands.

https://geneuro.ch/data/news/GeNeuro-PR-ECTRIMS-2022-curtain-raiser-ENG-Oct.-25-2022.pdf

GeNeuro: financial information for the third quarter 2022

Geneva, Switzerland, October 24, 2022, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today reported on its 2022 third quarter cash position and issued a business update.

https://geneuro.ch/data/news/GeNeuro-PR-Q3-2022-EN-Oct.-24-2022.pdf

Presentation at the International Society of NeuroVirology 2022 of top-line data of academic collaborations further documenting the long-term expression of the Proinflammatory and Neuropathogenic W-ENV protein in cohorts of post-COVID Patients 

Geneva, Switzerland, October 17, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), announced today that its Chief Scientific Officer, Dr. Hervé Perron, unveiled new data further documenting the presence of W-ENV in cohorts of post-COVID patients at the18th Symposium of the International Society of Neuro Virology (ISNV) held on October 11-14, 2022.

https://geneuro.com/data/news/GeNeuro-ISNV-presentation-ENG-Oct.-17-2022.pdf

Two studies on ALS published in Annals of Neurology demonstrate the neurotoxic role of human endogenous retrovirus envelope protein (HERV-K/HML-2 ENV) and the rationale for targeted therapy with specific antibody

Geneva, Switzerland, August 30, 2022 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19 (post-COVID), announced today the joint publications in the leading scientific journal “Annals of Neurology” of the results of the collaboration between GeNeuro and the National Institute of Neurological Disorders and Stroke (NINDS). NINDS is part of the National Institutes of Health (NIH) of the United States. The two publications describe the novel pathogenic mechanism of HERV-K in sporadic ALS and confirm the rationale for the therapeutic relevance of GeNeuro’s antibody to neutralize this neurotoxic protein.

https://geneuro.ch/data/news/2022-08-30-GeNeuro-PR-2-publications-ALS-Annals-of-Neurology.pdf

GeNeuro: financial information and business update for the second quarter 2022

Geneva, Switzerland, July 21, 2022, 5.45 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 second quarter cash position and issued a business update.

https://geneuro.ch/data/news/GeNeuro-PR-Q2-2022-EN-VF.pdf

Study confirming the key role of human endogenous retroviruses (HERV-K) for ALS published in “Annals of Neurology”

Geneva, Switzerland, July 20, 2022 – 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), announced today the publication in the leading scientific journal “Annals of Neurology” of the results of the collaboration between GeNeuro and the National Institute of Neurological Disorders and Stroke (NINDS). NINDS is part of the National Institutes of Health (NIH) of the United States. This publication describes the novel pathogenic mechanism of HERV-K in sporadic ALS and confirms the action of GeNeuro’s antibody to neutralize this toxicity.

https://geneuro.com/data/news/GeNeuro-PR-publication-SLA-EN-vf.pdf